Comparative in vitro activities of SMT19969, a new antimicrobial agent, against Clostridium difficile and 350 gram-positive and gram-negative aerobic and anaerobic intestinal flora isolates

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 10, 2013, Pages 4872-4876

  Goldstein, Ellie J C ^a,b   Citron, Diane M ^a   Tyrrell, Kerin L ^a   Merriam, C Vreni ^a  

^a R M ALDEN RESEARCH LABORATORY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; FIDAXOMICIN; METRONIDAZOLE; SMT 19969; UNCLASSIFIED DRUG; VANCOMYCIN;

ARTICLE; BACTERIUM ISOLATE; BACTEROIDES FRAGILIS; CLOSTRIDIUM; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM PERFRINGENS; DILUTION; EGGERTHELLA LENTA; ENTEROCOCCUS FAECALIS; FINEGOLDIA MAGNA; GRAM NEGATIVE AEROBIC RODS AND COCCI; GRAM NEGATIVE ANAEROBIC BACTERIA; GRAM POSITIVE BACTERIUM; IN VITRO STUDY; INTESTINE FLORA; LACTOBACILLUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PEPTOSTREPTOCOCCUS; PEPTOSTREPTOCOCCUS ANAEROBIUS; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; BACILLUS; BACTERIA, AEROBIC; BACTERIA, ANAEROBIC; BIFIDOBACTERIUM; CLOSTRIDIUM DIFFICILE; ENTEROCOCCUS FAECALIS; GRAM-POSITIVE BACTERIA; INTESTINES; MICROBIAL SENSITIVITY TESTS; PEPTOSTREPTOCOCCUS; STAPHYLOCOCCUS AUREUS;

EID: 84884222815     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01136-13     Document Type: Article

References (16)

1. Miller BA, Chen LF, Sexton DJ, Anderson DJ. 2011. Comparison of the burdens of hospital-onset, healthcare facility-associated Clostridium difficile infection and of healthcare-associated infection due to methicillinresistant Staphylococcus aureus in community hospitals. Infect. Control Hosp. Epidemiol. 34:387-390.
2. Gerding DN, Johnson S. 2010. Management of Clostridium difficile infection: thinking inside and outside the box. Clin. Infect. Dis. 51:1306-1313.
3. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. 2007. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin. Infect. Dis. 45:302-307.
4. Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, Gorbach S, Sears P, Shue YK, OPT-80-003 Clinical Study Group. 2011. Fidaxomicin versus vancomycin for Clostridium difficile infection. N. Engl. J. Med. 364:422-431.
5. Cornely OA, Crook DW, Esposito R, Poirier A, Somero MS, Weiss K, Sears P, Gorbach S, OPT-80-04 Clinical Study Group. 2012. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the U.S.A.: a double-blind, non-inferiority, randomized controlled trial. Lancet Infect. Dis. 12:281-289.
6. Goldstein EJC, Citron DM, Sears P, Babakhani F, Sambol SP, Gerding DN. 2011. Comparative susceptibilities of fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two fidaxomicin phase III trials of Clostridium difficile infection. Antimicrob. Agents Chemother. 55:5194-5199.
7. Louie TJ, Emery J, Krulicki W, Byrne B, Mah M. 2009. OPT-80 eliminates Clostridium difficile and is sparing of Bacteroides species during treatment of C. difficile infection. Antimicrob. Agents Chemother. 53:261-263.
8. van Nood E, Vrieze A, Nieudorp M, Fuentes S, Zoetendal EG, de Vos WM, Visser CE, Kuijper EJ, Bartelsman JF, Tijssen JG, Speelman P, Dijkgraaf MG, Keller JJ. 2013. Duodenal infusion of donor feces for recurrent Clostridium difficile. N. Engl. J. Med. 368:407-415.
9. Vickers R, Tinsley J, Storer R, Wilson F, Dorgan C, Wren S, Wilcox M, Baines S, Freeman J, Morrissey I, Maher K, Knight D. 2011. SMT-19969-a novel antibiotic for C. difficile infection: C. difficile growth inhi-bition, spectrum and resistance development. Abstr. 51st Intersci. Conf. Antimicrob. Agents Chemother., abstr. B-1194.
10. Weiss WJ, Vickers R, Pulse M, Nguyen P, Renick P, Simecka JW. 2011. Efficacy of SMT 19969 in a hamster model of C. difficile associated disease (CDAD). Abstr. 51st Intersci. Conf. Antimicrob. Agents Chemother., abstr. B-1195.
11. Baines SD, Freeman J, Huscroft GS, Todhunter SL, Wilcox M, Vickers R. 2011. Efficacy of novel antimicrobial; SMT 19969 in a simulated Clostridium difficile infection (CDI) in a simulated human gut model. Abstr. 51st Intersci. Conf. Antimicrob. Agents Chemother., abstr. B-1193.
12. Fawley WN, Wilcox MH. 2011. An enhanced DNA fingerprinting service to investigate potential Clostridium difficile infection case clusters sharing the same PCR ribotype. J. Clin. Microbiol. 49:4333-4337.
13. Jousimies-Somer HR, Summanen P, Citron DM, Baron EJ, Wexler HM, Finegold SM. 2002. Wadsworth-KTL anaerobic bacteriology manual. Star Publishing, Belmont, CA.
14. Versalovic J, Carroll KC, Jorgensen JG, Funke G, Landry ML, Warnock DW (ed). 2011. Manual of clinical microbiology, 10th ed, vol 2. ASM Press, Washington, DC.
15. Clinical and Laboratory Standards Institute. 2012. Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard, 8th ed. CLSI document M11-A8. CLSI, Wayne, PA.
16. Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility testing of bacteria that grow aerobically. Approved standard, 8th ed. CLSI document M7-A9. CLSI, Wayne, PA.